As of 1 May 2026, the European Union’s Medical Device Regulation (MDR) transition period concludes, mandating that all CT scanners placed on the EU market with AI-powered imaging enhancement, lesion detection, or dose optimization algorithms must submit an independently verified AI algorithm report issued by an EU Notified Body. This requirement directly impacts medical imaging manufacturers, regulatory affairs professionals, and importers operating in or supplying to the EU healthcare technology sector — because non-compliance results in removal from EUDAMED and loss of market access.

Event Overview

The EU Medical Device Regulation (MDR) transition period ends on 1 May 2026. From that date, CT scanners marketed in the EU containing AI-based image processing functions must be accompanied by an ‘AI Algorithm Independent Verification Report’ issued by an EU Notified Body. The report must confirm conformity with EN IEC 62304:2023 (software lifecycle processes), EN IEC 62366-1:2023 (usability engineering), and relevant high-risk provisions under the EU AI Act. Devices without such verification will be removed from the EUDAMED database and prohibited from sale in the EU.

Industries Affected

Medical Imaging Equipment Manufacturers

Manufacturers of CT systems integrating AI algorithms are directly subject to the requirement. Their products must undergo formal third-party verification before CE marking renewal or initial certification. Impact includes extended time-to-market, increased documentation burden, and potential redesign of software development and validation workflows to align with EN IEC 62304:2023 and EU AI Act obligations.

Regulatory Affairs & Certification Service Providers

Firms offering regulatory strategy, technical file preparation, or Notified Body liaison services face heightened demand for expertise in both MDR and EU AI Act compliance. The need to coordinate across two overlapping regulatory frameworks — one device-focused, the other AI-specific — increases complexity in submission planning and audit readiness.

EU Importers & Authorized Representatives

Importers and EU-based Authorized Representatives assuming legal responsibility for devices must verify that AI verification reports are complete, valid, and issued by a designated Notified Body. Failure to confirm this may result in liability for non-compliant devices placed on the market after 1 May 2026.

Distribution & Aftermarket Service Providers

Distributors and service providers supporting legacy or field-upgraded CT systems must assess whether installed AI features fall within scope. If post-market software updates introduce or enhance AI functionality covered by the regulation, re-verification may be triggered — affecting deployment timelines and support contracts.

Key Considerations and Recommended Actions

Monitor official guidance from EU Notified Bodies and the MDCG

While the legal deadline is fixed, interpretation of ‘AI algorithm’ scope — particularly for embedded, non-autonomous, or vendor-agnostic enhancements — remains subject to clarification. Stakeholders should track updates from the Medical Device Coordination Group (MDCG) and individual Notified Bodies regarding accepted verification methodologies and evidence expectations.

Prioritize verification for high-volume or newly launched CT models

Given limited capacity at Notified Bodies and multi-month lead times for AI-specific assessments, manufacturers should identify priority product lines early. Models with recently updated AI features, those entering new EU tenders, or those due for MDR recertification in H2 2025–H1 2026 warrant immediate internal readiness review.

Distinguish between regulatory signal and operational implementation

The requirement reflects a binding legal obligation, not a pilot or recommendation. However, enforcement posture — including timelines for grace periods, handling of pending applications, or transitional arrangements for already-certified devices — is still evolving. Companies should treat the 1 May 2026 date as definitive for new submissions, while treating enforcement details as subject to ongoing monitoring.

Prepare documentation and cross-functional alignment now

AI verification requires input from software development, clinical evaluation, usability testing, and quality assurance teams. Initiating internal gap assessments, updating design history files per EN IEC 62304:2023, and mapping AI functionality against EU AI Act Annex III criteria should begin no later than Q3 2025 to avoid bottlenecks.

Editorial Perspective / Industry Observation

Observably, this requirement marks the first enforceable intersection of MDR and the EU AI Act for diagnostic imaging hardware. It does not introduce new AI legislation but enforces existing frameworks in tandem — signaling regulators’ intent to treat AI components as integral, auditable parts of medical devices rather than ancillary software. Analysis shows this is less a standalone policy shift and more a hardening of prior guidance: the MDCG’s 2023 guidance on AI/ML-enabled medical devices already pointed toward independent verification, and the EU AI Act’s classification of medical imaging AI as ‘high risk’ set the stage. Current implementation timing suggests it functions primarily as a compliance checkpoint — not an innovation barrier — but its real-world impact will depend on Notified Body capacity and consistency in assessment outcomes.

Conclusion
This mandate underscores a structural evolution in EU medical device oversight: AI functionality is no longer treated as optional or post-market add-on, but as a core, regulated subsystem requiring pre-market verification. For stakeholders, it is best understood not as an isolated deadline, but as a procedural milestone confirming that AI integration in diagnostic imaging has entered a mature, accountable phase under EU law — one demanding coordinated technical, regulatory, and quality infrastructure.

Information Sources
Main source: Official EU MDR transitional provisions (Regulation (EU) 2017/745), as confirmed by European Commission communications and MDCG guidance documents (MDCG 2023-05, MDCG 2023-09).
Note: Ongoing verification practices by Notified Bodies and enforcement interpretations remain subject to observation beyond 1 May 2026.